Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4969411 | 0.88 | MAOB (0.50) | MAOBCYP19A1NISCHALDH1A1MAPT | |
| SCHEMBL30991548 | 0.82 | NISCH (0.40) | MAOBCYP19A1NISCHMAPT | |
| SCHEMBL4968442 | 0.82 | NISCH (0.40) | MAOBCYP19A1NISCHMAPTKIF11 | |
| SCHEMBL9177187 | 0.80 | NISCH (0.58) | MAOBCYP19A1NISCHALDH1A1MAPT | |
| SCHEMBL30991556 | 0.77 | MAOB (0.41) | MAOBCYP19A1NISCHALDH1A1MAPT | |
| SCHEMBL22791448 | 0.76 | CREBBP (0.46) | MAOBNISCHALDH1A1MAPT | |
| SCHEMBL7345041 | 0.76 | CREBBP (0.46) | MAOBNISCHALDH1A1MAPT | |
| SCHEMBL22570946 | 0.75 | BRD4 (0.45) | MAOBNISCHALDH1A1MAPT | |
| SCHEMBL2399683 | 0.73 | TSHR (0.45) | MAOBCYP19A1 | |
| SCHEMBL30991550 | 0.73 | MAOB (0.50) | MAOBCYP19A1NISCHALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193728-B2 | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-08-15 | — | — | US | disclosed |
| WO-2011103460-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103460-A1 | FUSED TETRACYCLIC PYRIDO[4,3-B]INDOLE AND PYRIDO[3,4-B]ONDOLE DERIVATIVES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210803-A1 | FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE | HTR4, HTR3B, HTR2C | MAOB 22/4885CYP19A1 3386/4885NISCH 1199/4885 |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | MAOB 2759/4885CYP19A1 2462/4885NISCH 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.